跳至主要内容
临床试验/NCT00913328
NCT00913328已完成4 期

Effect of Add-on Montelukast to Inhaled Corticosteroids in Excessive Airway Narrowing in Adults With Asthma

Hvidovre University Hospital0 个研究点目标入组 31 人开始时间: 2002年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
31
主要终点
Changes from baseline in maximal FEV1 decline at the dose-response plateau

研究概览

简要总结

Leukotriene receptor antagonists appear to posses additive anti-inflammatory effects to the effect of inhaled corticosteroids.

Hypothesis: Treatment with oral montelukast will lower the dose-response plateau to inhaled methacholine in patients with mild to moderate persistent asthma treated with a stable dose of inhaled corticosteroids.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Non-smoking adults with mild to moderate persistent asthma:
  • FEV1 > 70 % pred
  • PD20 methacholine < 3.9 mmol
  • treated for at least 3 months with a stable dose of inhaled corticosteroids
  • Documented dose-response plateau to inhaled methacholine on two occasions
  • Males and non-pregnant females

排除标准

  • Asthma medication other than inhaled corticosteroids and inhaled b2-agonists
  • Viral respiratory tract infections within the 3 weeks prior to enrollment

研究组 & 干预措施

Montelukast

Active Comparator

Oral montelukast 10 mg once daily for 12 weeks

干预措施: Montelukast (Singulair) (Drug)

Placebo

Placebo Comparator

Oral placebo once daily for 12 weeks

干预措施: Placebo (Drug)

结局指标

主要结局

Changes from baseline in maximal FEV1 decline at the dose-response plateau

时间窗: After 12 weeks of treatment

次要结局

  • Changes from baseline in PD20 methacholine(After 12 weeks of treatment)

研究者

申办方类型
Other

相似试验